Press Releases
Latest insights, analysis, and updates from our experts.
Lab-on-a-chip Diagnostic Systems Market is expected to reach USD 15.1 billion by 2031
The Lab-on-a-Chip Diagnostic Systems Market is growing rapidly as more people want quick, portable, and inexpensive diagnostic solutions in all healthcare environments. By combining various laboratory functions on a single microchip, these systems can deliver quicker results while using fewer samples and maintaining better accuracy. Besides that, ramping up the occurrence of infectious and lifestyle diseases, greater reliance on point-of-care testing, and progress in microfluidics and biosensor technologies are the main reasons for the market growth.
Bioengineered Proteins and Enzymes Market is expected to reach USD 11.5 billion by 2031
The rise in the demand for biological products like biologics, industrial enzymes, and sustainable bioprocessing solutions from the pharmaceutical, food & beverage, agriculture, and biotechnology industries are fueling the growth of these enzymes and proteins as bioengineered products. Proteins and enzymes with high efficiency and specific applications are being developed with ever increasing efficiency, thanks to the recombinant DNA technology, synthetic biology and protein engineering. Moreover, the growing investments for biopharmaceutical production, diversified application area in diagnostics and therapeutics, and the growing use of enzyme-based processes in the industrial sector are further pushing the market forward.
Biopharmaceutical Contract Development and Manufacturing (CDMO) Market is expected to reach USD 32.7 billion by 2031
The biopharmaceutical contract development and manufacturing (CDMO) market is seeing a surging uptake in outsourcing by pharmaceutical and biotechnology companies, the growing number of biopharmaceuticals being developed, and a demand for scalable and cost-efficient manufacturing solutions. The CDMOs offer clients integrated services in drug development, clinical and commercial manufacturing, and packaging, helping them to get to market faster and ensure regulatory compliance. As biologic, biosimilar and advanced therapies become more complex, the need for specialty CDMO partners is increasing at an even more rapid pace.
Synthetic Biology Healthcare Applications Market is expected to reach USD 21.9 billion by 2031
The healthcare applications of synthetic biology are rapidly evolving from exploratory research to regulated therapeutic commercialisation, through 2025-2026 government-backed initiatives in biologics, artificial intelligence (AI)-assisted molecular engineering and programmable cellular therapeutics. In 2025, the U.S. Food and Drug Administration (FDA) received 46 Novel Drug Applications (NDAs) reporting novel biologics and/or advanced therapy, indicating that the regulatory framework for engineered biological platforms is becoming more accepting and systematic over time. In addition, OECD's "2025 Technology Assessment" identified AI and robotics integrated with synthetic biology as one of the most significant drivers of disruptive innovation in healthcare, primarily within the areas of protein engineering, genomic medicine, and automated therapeutic discovery. While these AI-supported research programs are being developed, it should be noted that National Institutes of Health (NIH)-sponsored research is also developing the custom-protein design capabilities for precision therapeutics, immunotherapy optimisation, and next-generation biologics development.
Smartphone-enabled Diagnostic Platforms Market is expected to reach USD 27.9 billion by 2031
The rising adoption of digital health technologies, growing demand for point-of-care testing, and growing use of smartphones in healthcare monitoring and diagnostics are driving the strong growth of the smartphone-enabled diagnostic platforms market. The development of portable, real-time and user-friendly diagnostic solutions is being made possible by the development of biosensors, microfluidics, artificial intelligence (AI) and imaging technologies. Furthermore, rising incidence of chronic diseases, a growing emphasis on remote patient monitoring, and a growing healthcare accessibility in emerging economies are driving market growth.
Home-Based Diagnostic Testing Solutions Market is anticipated to surpass US$ 39.9 billion in 2031 at a CAGR of 9.1%
The home-based diagnostic testing solutions market is expanding rapidly due to rising consumer demand for convenient, affordable healthcare and preventive monitoring. Technological advancements, telehealth integration, and growing chronic disease prevalence are driving adoption. North America leads the market, while Asia Pacific shows strong growth potential supported by digital healthcare expansion and e-commerce accessibility.
Wearable Diagnostic Biosensors Market is expected to reach USD 42.9 billion by 2031
The Growth in the wearables diagnostic biosensor market is driven by increased prevalence of chronic diseases; a shift toward using remote patient monitoring technologies; and a greater integration of AI-enabled healthcare technologies into wearable devices. According to WHO, 43 million people die from noncommunicable diseases every year, accounting for 75% of deaths worldwide in 2025. The FDA expanded its approvals in 2025 for continuous glucose monitoring and cardiac monitoring devices that use biosensors, facilitating clinical adoption. Moreover, the European Commission reported that European investment in digital health infrastructure and wearable medical devices grew through the EU4Health Programme in 2025, accelerating commercialization and integration of wearable biosensor diagnostics into healthcare systems around the world.
Digital Twin Models For Pharmaceutical R&D Market is anticipated to surpass US$ 1.25 billion in 2031 at a CAGR of 15.4%
The digital twin models for the pharmaceutical R&D market is expanding rapidly as pharmaceutical companies adopt AI-driven simulation technologies to improve drug discovery, clinical trials, and manufacturing efficiency. North America leads the market, while AI and machine learning drive innovation. Increasing demand for personalized medicine and reduced development costs continues to accelerate global adoption.
Pharmacogenomics Platforms Market is expected to reach USD 10.1 billion by 2031
The pharmacogenomics platforms market is expanding at a rapid pace. Personalized medicine and genomic testing are the factors pushing the sales of pharmacogenomics products. Companion diagnostics for the treatment of various diseases also lead to demand for pharmacogenomics platforms. Drug-response analysis is becoming easier and faster due to innovative NGS, PCR, and bioinformatics platforms. The use of AI-based tools for precision medicine is one of the key market drivers. Predictive analytics, biomarker discovery, and genomic interpretation are the major areas that have been impacted by AI technologies.
Digital Biomarkers for Clinical Diagnostics Market is expected to reach USD 22.9 billion by 2031
The global digital biomarkers in clinical diagnostics market is experiencing robust growth because of the growing use of digital health technologies and the necessity to monitor patients constantly, in real-time. Digital biomarkers exploit data gathered by wearable devices, smartphones, and other connected health platforms to provide objective, quantifiable measures of the physiological and behavioral states. These biomarkers allow early diagnosis, disease surveillance and personalized treatment options in place of a large spectrum of clinical disorders.
Companion Diagnostics For Targeted Therapies Market is expected to reach USD 15.1 billion by 2031
In 2025, there will be a rapid expansion of the companion diagnostics-targeted therapies ecosystem due to a combination of growing precision medicine use and new and improved regulatory compliance with organisations such as the U.S. Food and Drug Administration, which will be the driving force behind this development. Companion diagnostics (CDx) are in vitro diagnostic (IVD) devices designed to help physicians use targeted drugs by identifying the required biomarkers in patients before they begin treatment.The U.S. FDA approved 46 new drugs in 2025, primarily drugs associated with drug treatment strategies based on biomarkers, and numerous new companion diagnostic devices to accompany these drugs to diagnose patients with malignant neoplasms of the lung, breast, and ovary to ensure appropriate patient selection for such therapies as immunotherapy and kinase inhibitors.Regulatory strategies aimed at reclassifying specific tests for companion diagnostics are being discussed to expedite test approvals and thus provide greater access to testing for patients, which will support the continuing growth of the convergence of the diagnostic and therapeutic markets.
Biomarker-Based Disease Detection Market is anticipated to surpass US$ 107.1 billion in 2031 at a CAGR of 11.0%
The global biomarker-based disease detection market is growing rapidly, driven by rising demand for personalized medicine, early disease diagnosis, and targeted therapies. Advances in genomics, immunoassays, and next-generation sequencing are improving diagnostic accuracy. North America leads the market, while Asia Pacific shows strong growth potential due to expanding healthcare infrastructure.